Our Website Uses Cookies
We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.
For more information, please contact us or consult our Privacy Notice.
Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
Daniel Pavin is a partner in the Corporate Practice and is resident in Covington's London office.
Mr. Pavin has broad non-contentious and contentious experience, with an emphasis on advising companies for whom intellectual property rights are of paramount importance. In particular, Mr. Pavin advises life sciences clients on their licensing, partnering, collaboration and other strategic and commercial agreements, and on the IP aspects of mergers, acquisitions and strategic investments in the life sciences and technology sectors. His contentious experience includes advising on contract disputes.
He serves as one of the leaders of Covington’s multidisciplinary Digital Health Initiative, which brings together the firm’s considerable resources across the broad array of legal, regulatory, commercial, and policy issues relating to the development and marketing of digital health technologies.
In Chambers UK (2018), clients say "he handles negotiations very adeptly and is very easy to work with."
Mr. Pavin also has particular expertise in data protection and data security. He has advised clients on a wide range of matters in these areas, including document and data retention policies, data security breaches and contested subject access requests.
- Illumina on its partnership with Genomics England, to sequence up to 500,000 whole genomes for the NHS Genomic Medicine Service.
- GammaDelta Therapeutics, a company focussed on harnessing the unique properties of gamma delta (γδ) T-cells to develop transformational immunotherapies, on the formation of Adaptate Biotherapeutics, a spin-out company building on GammaDelta’s knowledge to modulate γδ T-cell activity using therapeutic antibodies, with the potential to trigger an immune response against cancer.
- Healthcare technology company Sensyne Health on:
- its collaboration agreement with Bayer to accelerate the clinical development of new treatments for cardiovascular disease using Sensyne Health’s proprietary clinical AI technology platform;
- its agreement with Jefferson Health to evaluate the clinical and commercial potential of its GDm-Health™ system in the United States;
- data protection matters in connection with its £60 million IPO on London’s AIM market; and
- strategic research and data processing agreements with the Chelsea and Westminster Hospital NHS Foundation Trust, the Oxford University Hospitals NHS Foundation Trust, and the South Warwickshire NHS Foundation Trust.
- BenevolentAI, an AI company developing and applying advanced technologies to accelerate the journey from data to medicine, on its acquisition of Proximagen Limited, a Cambridge, UK-based drug discovery and development company.
- GammaDelta Therapeutics Limited, on a strategic collaboration with Takeda to develop GammaDelta Therapeutics’ novel T cell platform, which is based on the unique properties of gamma delta (γδ) T cells derived from human tissues.
- Abingworth on the establishment of and investment in GammaDelta Therapeutics Ltd, an immunotherapy company. GammaDelta Therapeutics has been founded on pioneering research by Professor Adrian Hayday and Dr Oliver Nussbaumer at King's College London and the Francis Crick Institute, funded in part by Cancer Research UK, into gamma delta (γδ) T cells.
- Medical Research Council Technology, a UK-based medical research charity, in the structured sale of a portion of its royalty interests in Keytruda for U.S.$150 million (£115.6 million), the largest royalty monetization by a non-profit institution outside the United States.
- AstraZeneca, along with its global biologics research and development arm, MedImmune, on a collaboration with Moderna Therapeutics to discover, co-develop and co-commercialize messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers.
- AstraZeneca on its acquisition of the core respiratory business of Takeda.
- A leading provider of on-demand video streaming services on its successful claim against the developer of the underlying software platform for delivery up of source code.
- Illumina on its strategic alliance agreement with Genomics England in respect of sequencing genomes of patients with cancer and rare diseases, as part of a four-year UK government project to decode 100,000 human genomes.
- Isarna Therapeutics GmbH, a German biotechnology company, on a license agreement with Santaris Pharma A/S for access to Santaris' Locked Nucleic Acid technology to develop oligonucleotide product candidates.
- Innovacell on a collaboration and licensing agreement with Norgine for Europe (excluding Russia and Turkey), SADC and MENA regions in which Innovacell and Norgine will co-develop, and Norgine will commercialise, ICEF15 - an innovative personalised cell therapy to treat faecal incontinence.
- Sanofi on a research collaboration agreement with Danish biotech Gubra ApS focusing on the discovery of gut peptides in order to identify novel targets suitable for development of peptide-based drugs for treatment of people with diabetes and obesity.
- Pharming Group NV on its strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture and commercialisation of new products based on the Pharming technology platform, in which SIPI will have commercialisation rights for the Chinese market for all new products developed and Pharming will retain global rights ex-China.
- UCB in relation to its strategic partnership with Synosia Therapeutics in which Synosia granted UCB a licence for exclusive, worldwide rights to the development compound SYN-115 and rights to a second compound, SYN-118, for non-orphan indications, both compounds being in Phase II clinical development for the treatment of Parkinson’s disease.
- Minster Pharmaceuticals PLC, an AIM-quoted drug development company specializing in compounds for the treatment of neurological and psychiatric conditions, on intellectual property aspects of its recommended takeover by Proximagen Neuroscience PLC.
- Biocompatibles International plc on numerous transactional matters including:
- An option agreement with a major multinational Japanese pharmaceutical company in respect of Biocompatibles’ Drug-Eluting Bead Products in Japan;
- Distribution agreements with (among others) SciClone Pharmaceuticals and RITA Medical Systems, Inc (now AngioDynamics, Inc) in respect of Biocompatibles’ DC and LC Bead Products; and
- The sale of Biocompatibles’ cardiovascular business to Abbott Laboratories and eyecare business to the Cooper Group.
- Australian anti-infective drug development company, Biota Holdings Limited, on:
- UK intellectual property aspects of its acquisition of the key assets and programs of UK-based antibacterial drug discovery company, Prolysis Limited; and
- Its collaboration and licence agreement with a major multinational pharmaceutical company headquartered in Europe relating to a series of antivirals aimed at the treatment of respiratory syncytial virus (RSV).
- A global medical technology company in respect of a dispute regarding endeavors obligations in a patent and know-how licence for stabilization technology.
- Communications company, Telefónica O2 UK, on document and data retention and data protection matters.
- A range of clients, including service providers to the financial services sector, recruitment consultancies, pension trustees and media companies, on responding to data security breaches and potential liabilities arising from those breaches.
- The shareholders of Sibelius Software Limited, the world-leading music notation software developer, on its sale to Avid, the world leader in digital media creation tools for film, video, audio, animation, games, and broadcast professionals.
September 28, 2020, Covington Digital Health
In a new post on the Covington Inside Privacy blog, our colleagues discuss the passage of California’s AB 713, a bill that creates a new healthcare-related exemption under the California Consumer Privacy Act of 2018 (“CCPA”) for certain information that has been deidentified in accordance with the Health Insurance Portability and Accountability Act of 1996...… ...
August 13, 2020, Covington Digital Health
Our colleagues at the Inside Privacy blog have summarized a proposed bill in California (the Genetic Information Privacy Act) that would impose certain privacy obligations on direct-to-consumer genetic testing companies that go beyond the California Consumer Privacy Act. This summary may be of interest to entities that process genetic data in California.… ...
March 20, 2020, Covington Digital Health
To assist companies that are developing technology solutions to help predict, mitigate or contain the spread of COVID-19, our cross-practice digital health team has put together a checklist of considerations to keep in mind (available here). For additional guidance, please visit our COVID-19 Legal and Business Toolkit (available here).… Continue Reading
March 18, 2020, Covington Alert
To assist companies that are developing technology solutions to help predict, mitigate or contain the spread of COVID-19, our cross-practice digital health team has put together a checklist of considerations to keep in mind. For additional guidance, please visit our COVID-19 Legal and Business Toolkit or reach out to us at COVID19@cov.com.
March 9, 2020, Inside Privacy
In this final instalment of our series of blogs on the European Commission’s plans for AI and data, announced on 19 February 2020, we discuss some potential effects on companies in the digital health sector. As discussed in our previous blog posts (here, here and here), the papers published by the European Commission cover broad...… Continue Reading
March 9, 2020, Covington Digital Health
In this final instalment of our series of blogs on the European Commission’s plans for AI and data, announced on 19 February 2020, we discuss some potential effects on companies in the digital health sector. As discussed in our previous blog posts (here, here and here), the papers published by the European Commission cover broad...… Continue Reading
March 4, 2020, Covington Digital Health
On February 27, 2020 NHSX, the technology and digital unit of the NHS, published its draft Digital Health Technology Standard (the “Standard”) for consultation to stakeholders in the digital health space (the “Consultation”). The Consultation is open until 22 April, 2020 (and is available here). The Standard, which is based on existing industry and health...… ...
February 14, 2020, Covington Digital Health
The Institute of Global Health Innovation at Imperial College London has published a report called “NHS data: Maximising its impact on the health and wealth of the United Kingdom” (the “Report”).[1] The Report begins from the premise that the knowledge gleaned from the combination of patient health data and “big data” technologies has incredible potential...… ...
January 16, 2020
London—Covington represented Illumina on its partnership with Genomics England, to sequence up to 500,000 whole genomes for the NHS Genomic Medicine Service. This partnership is part of the wider ambition to analyse up to 5 million genomes by 2024, to enable the UK to maintain its position as a global leader in genomics. Under this partnership and guided by ...
May 20, 2019
NEW YORK—Covington advised LifeArc, a UK-based medical research charity, on its monetization of a portion of its royalties relating to Keytruda® for $1.297 billion (approximately £1 billion). This royalty monetization is the largest single-product royalty monetization ever done by a non-profit. The transaction closed on May 10, 2019, the culmination of efforts ...
April 25, 2019, Covington Digital Health
On April 19, 2019, the Department of Health and Human Services (HHS) announced a 30-day extension to the comment period for two rules proposed by the HHS Centers for Medicare & Medicaid Services (CMS) and the Office of the National Coordinator for Health Information Technology (ONC), originally published on March 4, 2019. These rules, discussed...… Continue ...
UK’s NICE releases newly updated Digital Health Technologies (DHT) Evidence Standards Framework
March 19, 2019, Covington Digital Health
Following on from the Evidence Standards Framework for DHTs published in December 2018 (the Original Standards, as reported in our previous blog post, here), the UK’s National Institute for Health and Care Excellence (NICE) recently published a newly updated version of the standards (the Updated Standards, available here). The Updated Standards were produced ...
March 7, 2019, Covington Digital Health
On March 4, 2019, the Department of Health and Human Services (HHS) published two proposed rules to improve patient access to personal health data. The two rules, issued by the HHS Centers for Medicare & Medicaid Services (CMS) and the Office of the National Coordinator for Health Information Technology (ONC), are intended to increase interoperability...… ...
February 25, 2019, Covington Digital Health
On 15 February 2019, the European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA) published their Joint Big Data Taskforce’s summary report (available here) setting out recommendations for understanding the acceptability of evidence derived from ‘big data’ in support of the evaluation and supervision of medicines by regulators. The Taskforce has ...
February 6, 2019
NEW YORK—Covington has advised Sensyne Health, the British clinical AI technology company, on its agreement with Jefferson Health to evaluate the clinical and commercial potential of its GDm-Health™ system in the United States. GDm-Health is a direct patient-to-clinician blood glucose monitoring management system specifically designed for the management of ...
January 22, 2019, Covington Digital Health
Wearable watches that help consumers obtain a better understanding of their eating patterns; wearable clothes that send signals to treating physicians; smart watches: they are but a few examples of the increasingly available and increasingly sophisticated “wearables” on the EU market. These technologies are an integrated part of many people’s lives, and in some ...
October 22, 2018, Covington Digital Health
On 17 October, the UK Government’s Department of Health and Social Care (DHSC) published a policy paper entitled “The future of healthcare: our vision for digital, data and technology in health and care” (the Policy Paper). The Policy Paper outlines the DHSC’s vision to use technology across the health and care system, from “getting the...… Continue Reading
October 15, 2018, Covington Digital Health
On 8 October, the European Medicines Agency (EMA) published a report (available here) setting out the progress it has made towards applying a common data model (CDM) in Europe. The EMA defines a CDM as “a mechanism by which raw data are standardized to a common structure, format and terminology independently from any particular study...… Continue Reading
August 17, 2018
LONDON—Covington has advised Sensyne Health on medical device regulatory and data protection matters in connection with its £60 million IPO on London’s AIM market. The firm also represented Sensyne Health in negotiating strategic research and data processing agreements with the Chelsea and Westminster Hospital NHS Foundation Trust, the Oxford University ...
June 26, 2018, Covington Digital Health
Earlier this year, President Trump signed into law the Bipartisan Budget Act of 2018 (BBA), which incorporates provisions from the Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 and improves access to telehealth services in Medicare Advantage. Pub. L. No. 115-123. Among other provisions impacting Medicare ...
May 8, 2018, Covington Digital Health
On 1 May, 2018 the Centre for Policy Studies (the “CPS”) published its latest paper on the UK’s National Health Service (the “NHS”) entitled “Powerful Patients, Paperless Systems: How New Technology Can Renew The NHS” (the “Paper”). The Paper advocates a “digital first NHS” that adopts a paperless system and enables patients to take full...… Continue Reading
May 7, 2018, Covington Digital Health
On April 26, Commissioner Gottlieb addressed the agency’s progress on FDA’s Digital Health Innovation Action Plan and announced several additional steps the agency is taking to advance the potential benefits of digital health. Here is a recap of the key updates: (1) Launch of New FDA Program to Apply Digital Health to Drugs As our...… Continue Reading
May 2, 2018, Covington Digital Health
On the April 25, 2018 the European Commission (the “Commission”) adopted a plan of action to enable the digital transformation of health and care in the Digital Single Market (the “Communication”), intended to put EU citizens at the centre of the healthcare system. This is to be achieved in three ways: 1. Citizens’ secure access...… Continue Reading
March 9, 2018, Covington Digital Health
On March 6, 2018, CMS announced the MyHealthEData initiative, which aims to give patients easier access to and control over their medical records. Announcing the initiative, CMS Administrator Seema Verma laid out a future where individuals will have access to their health data wherever they go and be able to share data with the push...… Continue Reading
February 26, 2018, Covington Digital Health
Inflection Point for IoT In a relatively short amount of time, the adoption of the Internet of Things (IoT) and its applications— from smart cars to the myriad of interconnected sensors in the General Service Administration building reminiscent of HAL 9000 from 2001: A Space Odyssey— has rapidly proliferated, providing significant opportunities and benefits. ...
February 21, 2018, Covington Digital Health
As 2018 gets underway, EHR vendors and users continue to face challenges and uncertainty. There are three legal and regulatory issues in particular that we think are important to watch over the next 10 months: Moving to the 2015 Edition Certification Criteria. Although CMS will not require hospitals or eligible professionals to use 2015 CEHRT...… Continue ...
Covington Represents Autifony Therapeutics in Collaboration and Option Deal with Boehringer Ingelheim
December 21, 2017
LONDON—Covington represented Autifony Therapeutics Limited in connection with an option and asset purchase agreement with Boehringer Ingelheim (BI), with respect to Autifony's Kv3.1/3.2 positive modulator platform. This agreement provides BI with an exclusive option to acquire Autifony’s Kv3.1/3.2 positive modulator platform, including Autifony's lead compound ...
Covington Represents MRCT in Royalty Monetization Deal
July 15, 2016
NEW YORK—Covington advised Medical Research Council Technology, a UK-based independent life science medical research charity, in its sale of a portion of the royalty stream associated with its cancer drug Keytruda® for $150 million (£115.6 million). Keytruda® (pembrolizumab), is a new generation treatment which stimulates the body’s immune system to fight ...
Covington Advises AstraZeneca on mRNA Collaboration
January 13, 2016
LONDON — Covington advised AstraZeneca, along with its global biologics research and development arm, MedImmune, on a new collaboration with Moderna Therapeutics to discover, co-develop and co-commercialize messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers. The collaboration is in addition to the agreement announced by the ...
December 17, 2015
LONDON, 17 December, 2015 — Covington advised AstraZeneca on its acquisition of Takeda’s respiratory business. Under the terms of the agreement, AstraZeneca will make a payment of $575 million, and approximately 200 staff will transfer to AstraZeneca upon completion. The deal will include the expansion of rights to roflumilast (marketed as Daliresp in the ...
Covington Advises Allergy Therapeutics on £11.5 Million Placement and License Agreement
November 23, 2015
LONDON, November 23, 2015 — Covington represented Allergy Therapeutics, the AIM-listed specialty pharmaceutical company specializing in allergy vaccines, in the placement of ordinary shares raising approximately £11.5 million. The placement was conducted through an accelerated bookbuilding process with Panmure Gordon & Co acting as financial adviser, nominated ...
February 27, 2015
LONDON, February 27, 2015 — Covington advised Heptares Therapeutics Limited on its announced sale to Sosei Group, a Tokyo-listed Japanese biopharmaceutical company with operations in Japan and the UK. Consideration consisted of $180 million cash at closing and up to an additional $220 million contingent upon the successful progression of Heptares’ pipeline and ...
November 17, 2014
LONDON, 17 November, 2014 — Covington is advising Indivior, formerly RB Pharmaceuticals, in the demerger transaction announced today from Reckitt Benckiser, a global consumer products company. The demerger is subject to the approval of RB shareholders. Indivior PLC will be a specialty pharmaceutical company focused on the treatment of addiction and closely ...
Negotiating and Drafting Termination Provisions
November 6, 2014, Informa Life Sciences’ Inaugural Conference on Pharmaceutical Licensing and Collaboration Agreements: Legal Considerations
August 5, 2014
LONDON, 5 August, 2014 — Covington & Burling advised Illumina on its partnership with Genomics England to provide infrastructure and expertise for a four-year project that aims to make the UK the world leader in genetic research into cancer and rare diseases, through funding research to decode 100,000 human genomes - a patient's personal DNA code. The deal is ...
7th DVFA Life Science Conference: Innovative Treatment Strategies for Cancer
May 7, 2014, DVFA GmbH
January 13, 2014
LONDON, 13 January, 2014 — Covington & Burling advised Isarna Therapeutics GmbH on an agreement with Santaris Pharma A/S whereby Isarna gains access to Santaris' Locked Nucleic Acid (LNA) technology to further develop its next generation oligonucleotide product candidates. Under the terms of the agreement, Isarna obtains rights to utilize Santaris Pharma's ...
January 9, 2014
LONDON, 9 January, 2014 — Covington & Burling advised Innovacell Biotechnologie AG on a collaboration and exclusive licensing agreement with Norgine BV. Under the terms of the agreement Innovacell and Norgine will co-develop, and Norgine will commercialise, ICEF15 - an innovative personalised cell therapy to treat faecal incontinence. The agreement territory ...
Covington Advises SeaChange International on Media Sale
May 24, 2012
LONDON, 24 May, 2012 — Covington & Burling advised SeaChange International, Inc., on the sale of its UK-based media services company, On Demand Group Limited, to Avail-TVN, a company backed by Carlyle Group. The sale is part of SeaChange’s strategy to transform the company into a pure-play software company. SeaChange is a leading global multi-screen video ...
Optimising the Agreement Structure
March 7, 2012, Pharmaceutical Licensing Group UK Training Course
March 5, 2012, Inside EU Life Sciences
Article originally published in PLC Life Sciences Handbook 2012 M&A in the life sciences sector has remained robust, driven by factors such as: The need to replenish shrinking product pipelines. The need to maintain revenues as patents on top-selling products expire. The strategic diversification of business lines. Expansion into emerging ...
2012, PLC Life Sciences Handbook 2012
Negotiation of Life Sciences Collaboration and Licence Agreements
November 14, 2011, Negotiating, Understanding and Drafting Commercial Contracts for the Pharmaceutical Industry Seminar
Covington Adds Four Partner Life Sciences Corporate Team
5/16/2011
LONDON, May 16, 2011 — Covington & Burling LLP adds a top life sciences corporate team to its London office, further enhancing its comprehensive global life sciences practice. Covington is pleased to announce that Paul Claydon, Natalie Diep, James Gubbins and James Halstead are joining Covington & Burling LLP as partners. They complement Covington’s highly ...
February 15, 2011
WASHINGTON, DC, February 15, 2011 — For the seventh time, Practical Law Company has awarded Covington & Burling LLP its worldwide first place ranking in the Life Sciences Regulatory Super League category. PLC also singled out Covington’s Antitrust/Competition, Corporate, and Insurance practices, along with lawyers from each group, in its practice-specific ...
Pharma Buy
October 14, 2010, Inside EU Life Sciences
Article originally published in The Lawyer on October 14, 2010 Despite global economic conditions, deal-making by large pharmaceutical companies has remained relatively buoyant, say Daniel Pavin, Grant Castle and Alexandra Pygall. Acquisitions in the pharmaceuticals sector are being driven by factors such as the need to replenish shrinking product pipelines, the ...
Effects of Economic and Industry Trends on Agreement Drafting
September 2010, International Pharma Licensing Symposium
Data Security Breach Notification
June 2010, Data Protection Finance Group Meeting
Covington Advises Minster Pharmaceuticals in Recommended Takeover by Proximagen Neuroscience
January 15, 2010
LONDON, January 15, 2010 — Covington & Burling LLP advised Minster Pharmaceuticals plc, the AIM-quoted drug development company specialising in compounds for the treatment of neurological and psychiatric conditions, in its recommended takeover by Proximagen Neuroscience plc. The terms of the all cash offer value Minster at £4.3 million. The Covington team ...
Data Security and Data Breaches: Being Prepared
October 2009, PDP 8th Annual Data Protection Compliance Conference
Early Stage Licensing and R&D
July 2009, IBC Pharmaceutical Law Summer School 2009
Negotiating and Drafting Performance Clauses
June 2009, Pharmaceutical Licensing Group Masterclass
5/14/2009
LONDON, May 14, 2009 — Covington & Burling LLP is pleased to announce the arrival of Daniel Pavin, who joins the firm’s leading European life sciences practice as a partner in London. Mr. Pavin is recognized as a leading life sciences transactional lawyer in the UK and Europe and brings extensive experience in the life sciences and healthcare sectors. He ...
Data Security Breaches
February 2009, Data Protection and Privacy in the Workplace 2009
Licensing and Collaboration Agreement Disputes: How to Avoid Them (and if you can't avoid them, how to resolve them)
October 2008, BioPartnering Europe
Who Wants to Be a Licensor?
September 2008, European Pharmaceutical Licensing Group’s Annual Meeting
Effective Strategies for Resolving Licensing and Collaboration Agreement Disputes
January 2008, Pharmaceutical Licensing Group's AGM
Commercial Considerations on Selecting The Ideal Provider and Protecting The Parties Through Due Diligence and Sound Contractual Agreements
June 2007, Optimising Strategic Partnerships for Clinical Trial Outsourcing
Industry Trends and Their Effect on Licence and Collaboration Agreement Terms
April 2007, Life Sciences Alliance World
Intellectual Property Protection in UK Academic-Business Partnerships
February 2007, UK Trade & Industry
Licensee/Licensor Disputes: What to Have in Mind When Drafting
December 2006, BioPharm Licensing Conference
Putting Layered Privacy Notices into Practice
September 2006, Financial Services Data Protection Conference
- Chambers UK, Life Sciences: Transactional (2012-2020)
- LMG Life Sciences Europe, Life Sciences Star - Financial & Transactional (United Kingdom) (2014-2015)
- IAM Patent 1000 - The World’s Leading Patent Practitioners, Recommended (2012-2019)
- Who's Who Legal, Life Sciences Transactional
- Legal 500 UK, Commercial Contracts (2016)
- Legal 500 UK, Pharmaceuticals and Biotechnology (2016)
- Legal 500 UK, IT and Telecoms (2016)
COVID-19: Legal and Business Toolkit
We are helping clients around the world navigate this evolving, complex situation.
Covington Digital Health Blog
Top 10 Questions During Ideation of Digital Health Solutions
Covington has created a list of Top 10 Questions for Ideation of Digital Health Solutions that can help lawyers contribute to the digital health ideation process.